PHARMACEUTICAL ACQUISITION

Lilly, a big name in medicine, is making a big move. They're buying Ventyx, a smaller company with a promising lineup of drugs. Ventyx's focus? Inflammation. They're working on small molecules that could treat a wide range of diseases caused by chronic inflammation. Think heart disease, brain disord

One major player in the genetic testing world, 23andMe, has made a significant move. They sold their massive genetic data bank to a drug company, Regeneron Pharmaceuticals. The deal is worth 256 million dollars. This data bank holds genetic information from around 15 million people. The sale happene